1. Generics Bulletin
  2. >>Leadership

Who’s Hired? Formycon Is Latest To Swap CEO

Follows Changes At The Top For Orion And Strides In Recent Months

 
• By Dave Wallace

Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.

Leadership change CEO wooden blocks
Several firms have seen changes at the top • Source: Shutterstock

Formycon has announced a change in leadership, after a busy few weeks for the biosimilars developer. Stefan Glombitza – who has served as the firm’s chief operating officer since 2016 – will step up to become CEO from 1 July, taking over from Carsten Brockmeyer, who is set to leave the firm’s executive board “as planned on 30 June 2022.”

Brockmeyer, who has served Formycon for nine years as CEO, will continue to support the company as a scientific advisor,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By Dave Wallace

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By Dean Rudge

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

IGBA Asks G7 To Consider Access Issues

 
• By Dave Wallace

The International Generic and Biosimilar medicines Association has set out three priority areas that it says should be considered by G7 leaders at the current summit in Alberta, Canada, as part of efforts towards ensuring access to health.